Finch Therapeutics Group (NASDAQ:FNCH) Trading Up 0.6% – Should You Buy?

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) shares shot up 0.6% on Monday . The company traded as high as $12.8920 and last traded at $12.8920. 157 shares traded hands during mid-day trading, a decline of 91% from the average session volume of 1,731 shares. The stock had previously closed at $12.82.

Finch Therapeutics Group Price Performance

The company has a market capitalization of $20.76 million, a PE ratio of -1.46 and a beta of 1.17. The stock has a 50-day simple moving average of $13.63 and a 200 day simple moving average of $13.19.

About Finch Therapeutics Group

Finch Therapeutics Group is a clinical-stage biopharmaceutical company focused on developing microbiome-based therapies to treat diseases driven by gut microbial imbalance. Leveraging its proprietary Microbial Ecosystem Therapeutics (MET) platform, Finch engineers defined consortia of live microbes designed to restore healthy microbiome function. Its lead candidate, CP101, is in late-stage development for prevention of recurrent Clostridioides difficile infection (rCDI), and the company is advancing additional programs in inflammatory bowel disease, autism spectrum disorder and other immune-mediated conditions.

Founded in 2015 as an outgrowth of research at Massachusetts General Hospital and the Massachusetts Institute of Technology, Finch Therapeutics is headquartered in Cambridge, Massachusetts.